Increasing Coverage of Antiretroviral Therapy and Male Medical Circumcision in HIV Hyperendemic Countries: A Cost-Benefit Analysis

Pascal Geldsetzer (), David Bloom, Salal Humair () and Till Bärnighausen ()
Additional contact information
Pascal Geldsetzer: Harvard School of Public Health
Salal Humair: Harvard School of Public Health
Till Bärnighausen: Harvard School of Public Health

No 9143, IZA Discussion Papers from Institute of Labor Economics (IZA)

Abstract: HIV continues to cause the largest number of disability-adjusted life years of any disease in HIV hyperendemic countries (i.e., countries with an adult HIV prevalence >15%). We compare the benefits and costs of two proven biological interventions to reduce the health losses due to the HIV epidemic in hyperendemic countries from 2015 through 2030: 1) increasing ART coverage to 90% among HIV-infected adults with a CD4-cell count

Keywords: HIV; male medical circumcision; antiretroviral therapy; cost-benefit analysis (search for similar items in EconPapers)
JEL-codes: D61 I18 (search for similar items in EconPapers)
Pages: 31 pages
Date: 2015-06
New Economics Papers: this item is included in nep-env and nep-hea
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://docs.iza.org/dp9143.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:iza:izadps:dp9143

Ordering information: This working paper can be ordered from
IZA, Margard Ody, P.O. Box 7240, D-53072 Bonn, Germany

Access Statistics for this paper

More papers in IZA Discussion Papers from Institute of Labor Economics (IZA) IZA, P.O. Box 7240, D-53072 Bonn, Germany. Contact information at EDIRC.
Bibliographic data for series maintained by Holger Hinte ().